What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Cancer
Internal medicine, Rheumatoid arthritis, Rheumatology, Surgery and Arthritis are his primary areas of study.
The Internal medicine study combines topics in areas such as Gastroenterology and Physical therapy.
His biological study spans a wide range of topics, including Infliximab and Disease.
His Rheumatology study incorporates themes from Transcutaneous electrical nerve stimulation, Manual therapy, Diacerein, Electrotherapy and Pharmacology.
His studies deal with areas such as Stroke, Adverse effect and Cohort as well as Surgery.
His study in Arthritis is interdisciplinary in nature, drawing from both Psoriasis, Endocrinology, Forceps and Pathology.
His most cited work include:
- Osteoarthritis: An Overview of the Disease and Its Treatment Strategies (305 citations)
- Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse (238 citations)
- Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group (237 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Rheumatoid arthritis, Immunology, Rheumatology and Arthritis.
His Internal medicine study combines topics in areas such as Gastroenterology and Surgery.
His research related to Prednisone and Prospective cohort study might be considered part of Surgery.
His research integrates issues of Physical therapy, Adverse effect and Clinical trial in his study of Rheumatoid arthritis.
His work in Autoantibody, Antibody, Connective tissue disease, Inflammation and Pathogenesis is related to Immunology.
His Arthritis research is multidisciplinary, relying on both Infliximab and Etanercept.
He most often published in these fields:
- Internal medicine (56.66%)
- Rheumatoid arthritis (41.65%)
- Immunology (20.08%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (56.66%)
- Rheumatoid arthritis (41.65%)
- Rheumatology (19.70%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Rheumatoid arthritis, Rheumatology, Disease and Cohort.
Roberto Caporali integrates Internal medicine and In patient in his research.
His study of Rheumatoid factor is a part of Rheumatoid arthritis.
His studies in Rheumatology integrate themes in fields like Systematic review, Randomized controlled trial and Clinical trial.
His research in Disease intersects with topics in Epidemiology and Family medicine.
While the research belongs to areas of Adverse effect, he spends his time largely on the problem of Tocilizumab, intersecting his research to questions surrounding Prednisone.
Between 2018 and 2021, his most popular works were:
- COVID-19 infection and rheumatoid arthritis: Faraway, so close! (210 citations)
- Baricitinib for COVID-19: a suitable treatment? (99 citations)
- What is the true incidence of COVID-19 in patients with rheumatic diseases? (54 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Cancer
Roberto Caporali mainly focuses on Internal medicine, Coronavirus disease 2019, Pandemic, Rheumatoid arthritis and Disease.
Internal medicine is closely attributed to Referral in his research.
His Pandemic research includes themes of Incidence, Pneumonia, Outbreak, Emergency medicine and Global health.
His Rheumatoid arthritis study combines topics from a wide range of disciplines, such as Pregnancy, Arthritis, Immune system, Biomarker and Active inflammation.
His Arthritis study deals with the bigger picture of Immunology.
His work deals with themes such as Risk factor and Intensive care medicine, which intersect with Disease.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
